Kolexia
Drenou Bernard Hématologie
Drenou Bernard
Hématologie
Hôpital Emile Muller
Mulhouse, France
146 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Lymphomes Leucémie chronique lymphocytaire à cellules B Leucémie lymphoïde COVID-19 Maladie de Hodgkin Lymphome malin non hodgkinien Anémie Maladie résiduelle

Collaborateurs

Voir plus
Debliquis Agathe
Debliquis Agathe
Hôpital Emile Muller, Mulhouse, France
Arkam Yazid
Arkam Yazid
Hôpital Emile Muller, Mulhouse, France
Harzallah Inès
Harzallah Inès
Hôpital Emile Muller, Mulhouse, France
Newinger Muriel
Newinger Muriel
Hôpital Emile Muller, Mulhouse, France

Industries

Voir plus
B3TSI
20 collaboration(s)
Dernière en 2023
Janssen
14 collaboration(s)
Dernière en 2023
Abbvie
14 collaboration(s)
Dernière en 2023
AstraZeneca
10 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
MorningLyte: A Phase III Randomized, Open-label, International, Multicenter Study Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide in Comparison to Anti-CD20 Monoclonal Antibody Plus Chemotherapy in Subjects With Previously Untreated FLIPI 2-5 Follicular Lymphoma
Essai Clinique (The Lymphoma Academic Research Organisation)   13 mars 2024
Stem Cell Responsiveness to Imatinib in Chronic Myeloid Leukemia.
International journal of molecular sciences   23 novembre 2023
Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group
65th ASH Annual Meeting Abstracts   02 novembre 2023
Neutrophil PNH Type II Cells Are Associated with Thrombosis and Bone Marrow Failure without Hemolysis: Evidence from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Lenalidomide Consolidation Improves Measurable Residual Disease (MRD) Rates and Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
65th ASH Annual Meeting Abstracts   02 novembre 2023
Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort.
Blood advances   24 octobre 2023
Normal B cells express ZAP70 in chronic lymphocytic leukemia: A link between autoimmunity and lymphoproliferation?
American journal of hematology   19 octobre 2023
THEMIS: Targeted Therapies in Chronic Lymphocytic Leukemia and Medico-economic Evaluation of the Ambulatory Medical Assistance Nurse Program : a Prospective Multicenter Randomized Study
Essai Clinique (CHU Toulouse)   18 septembre 2023
Quality of life and response shift effect of diffuse large B-cell lymphoma French patients included in prospective real-life REALYSA cohort in the first year after diagnosis
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023   09 juin 2023
Deciphering the Cardiovascular Potential of Human CD34 Stem Cells.
International journal of molecular sciences   31 mai 2023